Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Source: SeekingAlpha
2025-02-04 19:41:27 ET
Summary
- Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients.
- Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma.
- But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient.
- Valuation-wise, I think FATE’s low P/B relative to peers shows it is cheap, even though that’s partially due to its early-stage pipeline.
- The main risk I see with FATE is its inherently speculative R&D progress, but also its cash burn, which could become an issue by 2027. Other than that, I rate FATE a “Buy”.
...
Read the full article on Seeking Alpha
For further details see:
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Fate Therapeutics Inc.
NASDAQ: FATE
FATE Trading
-11.36% G/L:
$1.755 Last:
1,018,709 Volume:
$1.86 Open:
FATE Latest News
May 13, 2026 08:30:00 am
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 11, 2026 08:30:00 am
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual MeetingFATE Stock Data
$128,041,041
108,996,378
1.54%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
